The document discusses the significant increase in the elderly population and the implications for medication use and management in geriatric healthcare. It highlights the challenges of polypharmacy, adverse drug events, and the need for careful monitoring and individualized treatment plans to optimize drug therapy for older adults. Additionally, it emphasizes the importance of ensuring quality care and avoiding ageism, while advocating for the dignity and autonomy of elderly patients.
Dr. D. K.Brahma
Associate Professor
Department of Pharmacology
NEIGRIHMS, Shillong
2.
 Demographic transition– a global
demographic event
 WHO – People 60 years of age and older is
650 million now and forecast to reach 2 Billion
by 2050
 Persons aged 65 years and older constitute
13% of the population and purchase 33% of
all prescription medications
 By 2040, 25% of the population will purchase
50% of all prescription drugs
3.
 Medications playcrucial role in geriatric health
care as they treat chronic diseases, alleviate pain
and improve quality of life
 Age-related changes in drug disposition and
pharmacodynamic responses have significant
clinical implications
 Increased use of a number of medications in
elderly raises the risk of medicine-related problems
that may occur
 Medication use and the incidence of adverse drug
outcomes increase with advancing age
 It is important to ensure quality use of medicines in
older people
4.
 Large numberof new drugs available each
year
 Off-label indications are expanding
 Advanced understanding of drug-drug
interactions
 Increasing popularity of “nutriceuticals”
 Multiple co-morbid states
 Polypharmacy
 Medication compliance
 Effects of aging physiology on drug therapy
 Medication cost
5.
Rate of absorptionmay be delayed
• Lower peak concentration
• Delayed time to peak concentration
Factors:
• Increased GI pH
• Decreased gastric emptying
• Dysphagia
• Route of administration
• Co-morbidity conditions
• Presence of drugs (pH and gastric emptying) and
additives
6.
Aging Effect VdEffect Examples
 body water  Vd for hydrophilic
drugs
ethanol, lithium
 lean body mass  Vd for drugs that
bind to muscle
digoxin
 fat stores  Vd for lipophilic
drugs
diazepam, trazodone
 plasma protein
(albumin)
 % of unbound or
free drug (active)
diazepam, valproic acid,
phenytoin, warfarin
Reduced amount of water in the body - fat soluble drugs remain longer in
the body with prolonged effects – of importance for some sedatives and
anxiolytics
7.
Pathway Effect Examples
PhaseI:
oxidation,
hydroxylation,
dealkylation,
reduction
Conversion
to
metabolites
of lesser,
equal, or
greater
diazepam,
quinidine,
piroxicam,
theophylline
Phase II:
glucuronidatio,
conjugation, or
acetylation
Conversion
to inactive
metabolites
lorazepam,
oxazepam,
temazepam
•Reduced liver function
•Hepatic microsomal
drug metabolizing activity
may be reduced due to:
decreased hepatic
blood flow
decreased liver size
and mass
Examples: morphine,
metoprolol, propranolol,
verapamil, amitryptyline,
nortriptyline (sensitivity to
beta-blockers reduced)
8.
 Reduced kidneyfunction - decreased excretion of
some cardiovascular drugs, some antibiotics,
diabetic drugs, antiinflammatory drugs – need to
reduce dosage
 Decreased kidney size
 Decreased renal blood flow
 Decreased number of functional nephrons
 Decreased tubular secretion
 Result:  glomerular filtration rate (GFR)
 Decreased drug clearance: atenolol, gabapentin,
H2 blockers, digoxin, allopurinol, quinolones
 Creatinine clearance (CrCl) is used to estimate
glomerular rate
9.
Brain and nervoussystem more sensitive
to psychotropic and analgesic drugs –
dizziness, confusion, cognitive impairment
Decreased capacity to regulate blood
pressure – blood pressure fall, fainting,
vertigo when using drugs for hypertension
Gastrointestinal sensitivity to anti-
inflammatory drugs - bleeding
10.
Balance between overprescribingand
underprescribing
• Correct drug
• Correct dose
• Targets appropriate condition
• Is appropriate for the individual patient
Avoid “a pill for every ill”
Always consider non-pharmacologic therapy
11.
Adverse drug events(ADEs)
Drug interactions
Duplication of drug therapy
Decreased quality of life
Unnecessary cost
Medication non-adherence
12.
 Responsible for5-28% of acute geriatric hospital
admissions
 Greater than 95% of ADEs in the elderly are
considered predictable (Type A) and approximately
50% are considered preventable
 Most errors occur at the ordering and monitoring
stages
 Most common medications associated with ADEs
in elderly
• Opioid analgesics
• NSAIDs
• Anticholinergics
• Benzodiazepines
• Also: cardiovascular agents, CNS agents, and
musculoskeletal agents
13.
High potential tocause severe ADEs in
elderly – amitriptyline, chlorpropamide,
digoxin >0.125mg/d, disopyramide,
antispasmodics, meperidine, methyldopa,
pentazocine, ticlopidine
High potential but less severe:
antihistamines, diphenhydramine,
dipyridamole, ergot mesyloids,
indomethacin, muscle relaxants
14.
ADE interpreted asnew
medical condition
Drug 1
Drug 2
ADE interpreted as new
medical condition
Drug 3
Rochon PA, Gurwitz JH. Optimizing drug treatment in elderly people: the prescribing cascase. BMJ 1997;315:1097.
15.
Combination Risk
ACE inhibitor+ potassium Hyperkalemia
ACE inhibitor + K sparing diuretic Hyperkalemia, hypotension
Digoxin + antiarrhythmic Bradycardia, arrhythmia
Digoxin + diuretic
Antiarrhythmic + diuretic
Electrolyte imbalance; arrhythmia
Diuretic + diuretic Electrolyte imbalance; dehydration
Benzodiazepine + antidepressant
Benzodiazepine + antipsychotic
Sedation; confusion; falls
CCB/nitrate/vasodilator/diuretic Hypotension
Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a
prospective study of 1000 patients. J Am Geriatr Soc 1996;44(9):944-948.
1. When meetingthe patient - get ready to spent more time and understand the
patient and his problems – see the whole patient as a part of whole
2. Identify the patient`s need of treatment – diagnosis important - Have a
comprehensive view
3. Symptoms can be adverse reactions to drugs
4. Record which other drugs the patient is using
5. Evaluate what has to be prescribed – make a benefit risk assessment, is there any
medication which should be stopped – must avoid Polypharmacy
6. Which dosage and administration form is appropriate
7. Make a plan for the treatment, when to meet for a follow-up of the effects of the
treatment and discuss this with the patient or her or his carer
• Use of lower doses, longer intervals, slower titration are helpful in decreasing the
risk of drug intolerance and toxicity
8. Careful monitoring is necessary to ensure successful outcomes
9. Remember:
• Balance between under prescribing and overprescribing
• Avoid “a pill for every ill”
• Always consider non-pharmacologic therapy
10. Report adverse reactions if they occur
18.
Always take utmostcare and responsibility
while prescribing medicines to an aged
patient – think, re-think, discuss with
colleague/seniors - if needed and apply
your best intellectual knowledge - Be
cautious with NSAIDS, CNS drugs, CVS
drugs, diuretics and oral hypoglycaemics
19.
Brahma DK, WahlangJB, Marak MD, Ch. Sangma M. Adverse drug reactions in the elderly. J Pharmacol Pharmacother [serial online] 2013 [cited 2017 Sep 24];4:91-4.
Available from: http://www.jpharmacol.com/text.asp?2013/4/2/91/110872
20.
We do notwant to meet ageism
We do not want to be discriminated
We want to keep our self-determination
We want to keep our dignity, integrity
We want to feel we are a resource
When in need, we want access to high
quality care and services including
palliative care
At the very end of life we should not
Barbro Westerholm.Prof.em, Member of Swedish Parliament. EFNS Stockholm 2012; Presentation - Healthy ageing and medicines - European Medicines
...www.ema.europa.eu/docs/en_GB/document_library/.../2012/.../WC500125120.pdf
21.
“To care forthose who once
cared for us is one of the
highest honours.”